Status:

COMPLETED

Implementation of Smoking Cessation Within NCI Community Oncology Research Program (NCORP) Sites

Lead Sponsor:

Wake Forest University Health Sciences

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Smoking Cessation

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Evaluate a multi-faceted training program to improve short-term smoking cessation rates (\<14 days post-visit) and short (3 months) and sustained abstinence (6 months) among 1,114 enrolled smokers who...

Detailed Description

We utilize an effectiveness-implementation hybrid design, employing a cluster, randomized control trial of community-based NCORP sites to study the effectiveness of a multi-faceted intervention to imp...

Eligibility Criteria

Inclusion

  • Agrees to have NCORP research personnel serve as the study liaison and another person to serve as the cessation program champion.
  • Agrees to participate in all aspects of the intervention, randomization, and evaluation.
  • Agrees to participate in a confidential 1-on-1 semi-structured interview with the research team.
  • Agrees to have the interview taped, transcribed and qualitatively analyzed.
  • Age ≥18 years
  • Potential participants will be screened using the following question: "Do you smoke cigarettes every day, some days, or not at all?" (BRFSS). A current smoker is anyone responds "every day" or "some days".

Exclusion

  • Current use (previous 30 days) of a tobacco dependence treatment including bupropion, varenicline, and nicotine replacement
  • Individuals who use e-cigarettes and who are not smoking cigarettes. Dual users (those who use both e-cigarettes and cigarettes) will still be included in the trial.
  • The presence of a physical or cognitive impairment that would prevent a person from engaging in survey research (such as blindness, deafness, or dementia).
  • Individual has already completed the intended LDCT lung cancer screening for this study.
  • Non-English speaking participants.

Key Trial Info

Start Date :

June 1 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 22 2021

Estimated Enrollment :

1094 Patients enrolled

Trial Details

Trial ID

NCT03291587

Start Date

June 1 2018

End Date

February 22 2021

Last Update

July 25 2022

Active Locations (49)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 13 (49 locations)

1

Helen F Graham Cancer Center

Newark, Delaware, United States, 19713

2

Augusta University Medical Center

Augusta, Georgia, United States, 30912

3

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler

Savannah, Georgia, United States, 31405

4

Tripler Army Medical Center

Honolulu, Hawaii, United States, 96859